Hepion Pharmaceuticals Announces 2026 Annual Meeting Results and Equity Plan Amendment

Hepion Pharmaceuticals, Inc. filed a Current Report on Form 8-K to announce the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders voted on three key proposals. First, they elected five directors to the Board: Gary Stetz (who also serves as Interim CEO), Vincent LoPriore, Michael Purcell, Sireesh Appajosyula, and Chase LoPriore, all of whom will serve until the next annual meeting. Second, the appointment of Grassi & Co., CPAs, P.C. as the company's independent auditors for the fiscal year ending December 31, 2026, was ratified with a significant majority. Finally, stockholders approved an amendment to the company's 2023 Omnibus Equity Incentive Plan. This amendment substantially increases the number of shares authorized for issuance under the plan from 200,000 to 8,000,000 shares. As of the record date, there were approximately 29.1 million shares of common stock outstanding and eligible to vote.